{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["N/A"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001004205"],"sample_count":["31"],"description":["EGA dataset EGAD00001004205"],"repository":["EGA"],"title":["Whole-exome sequencing of liver cancer organoids"],"pubmed_abstract":["Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second most frequent cause of cancer-related mortality worldwide. The multikinase inhibitor sorafenib is the only treatment option for advanced HCC. Due to tumor heterogeneity, its efficacy greatly varies between patients and is limited due to adverse effects and drug resistance. Current in vitro models fail to recapitulate key features of HCCs. We report the generation of long-term organoid cultures from tumor needle biopsies of HCC patients with various etiologies and tumor stages. HCC organoids retain the morphology as well as the expression pattern of HCC tumor markers and preserve the genetic heterogeneity of the originating tumors. In a proof-of-principle study, we show that liver cancer organoids can be used to test sensitivity to sorafenib. In conclusion, organoid models can be derived from needle biopsies of liver cancers and provide a tool for developing tailored therapies."],"pubmed_title":["Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies."],"pubmed_authors":["Nuciforo Sandro S, Fofana Isabel I, Matter Matthias S MS, Blumer Tanja T, Calabrese Diego D, Boldanova Tujana T, Piscuoglio Salvatore S, Wieland Stefan S, Ringnalda Femke F, Schwank Gerald G, Terracciano Luigi M LM, Ng Charlotte K Y CKY, Heim Markus H MH"],"additional_accession":[]},"is_claimable":false,"name":"e4c45bda-86ce-40aa-a3b6-64f2ad0482cc - samples","description":"Whole-exome sequencing was performed from organoids derived from 10 liver cancer biopsies (7 hepatocellular carcinoma and 3 cholangiocarcinoma), corresponding liver and non-tumoral biopsies. For 3 of the organoids, both early and late passage organoids were sequenced. Whole-exome sequencing was performed using the Agilent Clinical Research Exome capture kit followed by Illumina sequencing. BAM files are provided in this dataset.","dates":{"updated":"2019-01-07 08:54:28"},"accession":"EGAD00001004205","cross_references":{"TAXONOMY":["9606"],"pubmed":["30067989"],"EGA":["EGAC00001000964","EGAS00001003115"]}}